Another Disappointing Day

[Anonymous]

Ok peon, basic math. Topirimate market is 3 times the size of Oxcarbazepine. 41 x 3 = 123 and we did over 650rxs in wk 7.

Looks like we are over 5xs ahead of Oxtellar XR performance with Trokendi XR going into wk 8 post launch.

It is considerably more than 3x you d!psh!t.

 

[Anonymous]

It is considerably more than 3x you d!psh!t.

oxcarb = about 3 million rx/yr
topiramate = about 10 million rx/yr

Ok you're right tough guy, you got us. The topiramate market is 3.3x bigger than oxcarb. I guess you consider .3 "considerably more." I give you an A for effort in being so confident in your statement though "d!psh!t".

 

[Anonymous]

oxcarb = about 3 million rx/yr
topiramate = about 10 million rx/yr

Ok you're right tough guy, you got us. The topiramate market is 3.3x bigger than oxcarb. I guess you consider .3 "considerably more." I give you an A for effort in being so confident in your statement though "d!psh!t".

Haaaaa you know we don't target all 3 million oxcarb but you leave that out because it is convenient for your argument. But hey keep thinking that things are going well, soon you'll be looking for a new job.

 

[Anonymous]

oxcarb = about 3 million rx/yr
topiramate = about 10 million rx/yr

Ok you're right tough guy, you got us. The topiramate market is 3.3x bigger than oxcarb. I guess you consider .3 "considerably more." I give you an A for effort in being so confident in your statement though "d!psh!t".

Last numbers I saw we only target a little over 1M of the Oxcarb scripts when you remove the oral suspension and off label use but you already knew that didn't you

 

[Anonymous]

Haaaaa you know we don't target all 3 million oxcarb but you leave that out because it is convenient for your argument. But hey keep thinking that things are going well, soon you'll be looking for a new job.

Ok, you're right again. I looked and total targeted Rxs of oxcarb to topiramate was more than 3x. But was only about 5x which still backs someone else's earlier argument that trokendi xr is significantly outpacing oxtellar xr (I know, as it should be.)

The point is, this isn't kool aid drinking. We are doing better than when we were all essentially freshman reps new to the industry, and it's not just due to the size of the market.

I get that this company isn't perfect, and management tactics can be a bit over the top but I'm certainly happier and enjoying my job more than you are with my mindset. Seriously man, why so salty.

 

[Anonymous]

Ok, you're right again. I looked and total targeted Rxs of oxcarb to topiramate was more than 3x. But was only about 5x which still backs someone else's earlier argument that trokendi xr is significantly outpacing oxtellar xr (I know, as it should be.)

The point is, this isn't kool aid drinking. We are doing better than when we were all essentially freshman reps new to the industry, and it's not just due to the size of the market.

I get that this company isn't perfect, and management tactics can be a bit over the top but I'm certainly happier and enjoying my job more than you are with my mindset. Seriously man, why so salty.

Your tears are delicious.

 

[Anonymous]

Your tears are delicious.

Some men just want to watch the world burn